Q-omics provides the consensus-scored CCDC198 profile across patient tissues and cancer cell-line models. CCDC198 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, CCDC198 is differentially expressed in 11, with the highest sampling consensus in KICH. Additionally, CCDC198 RNA expression shows 15,689 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight KIRC, KICH, and KIRP as cancer lineages where CCDC198 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CCDC198 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CCDC198 survival associations across molecular data types. CCDC198 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (3) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CCDC198 RNA expression–survival associations across cancer types. High CCDC198 expression shows unfavorable associations in LIHC and DLBC, but favorable associations in KIRC, BLCA, KIRP and LAML. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for CCDC198 RNA expression.
This table summarizes CCDC198 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for CCDC198. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CCDC198 shows lower tumor expression in KICH, KIRC and UCEC and higher tumor expression in HNSC, LUAD and STAD. The KICH box plot shows higher CCDC198 RNA expression in normal versus tumor tissue (log2 FC = −3.592, t-test p < 0.001).
This table shows molecular features associated with CCDC198 in patient tissues and cancer cell lines. In patient samples, CCDC198 shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set. In cancer cell lines, CCDC198 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in KIDNEY and OVARY.
